Samsara Vision, Inc. (previously known as VisionCare Inc.) is a privately held specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders.
In the United States, our lead product, the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) (IMT), is the first and only FDA-approved implantable medical device demonstrated to improve vision and quality of life in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD), or late-stage AMD. Late-stage AMD results in a loss of central or “straight-ahead” vision, creating a blind spot that is uncorrectable by glasses, drugs, injections, or cataract surgery. It is the leading cause of blindness in older Americans. It is also approved in the EU, United Kingdom and Australia. Samsara Vision’s SING IMT™ received a CE mark for the European Union in 2020. (SING IMT is not currently FDA approved).
We believe that rejuvenating eyesight, revives the spirit, allowing people to reconnect to the things in life that they love to see and do. Our approach includes working collaboratively with health care providers, researchers, payers, and advocates to ensure that people living with deteriorating vision have access to our novel technologies and support paths thereby better ensuring a future where they can see anew.